A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors

A Phase 1 Study Of SU011248 And Gemcitabine In Patients With Advanced Solid Tumors

This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors

Inclusion Criteria:

• Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists
• Patient has good performance status (ECOG 0 or 1)

Exclusion Criteria:

• Prior treatment with either gemcitabine or SU011248
• Hypertension that cannot be controlled by medications